Cargando…

Adverse Reactions in a Phase 1 Trial of the Anti-Malarial DM1157: An Example of Pharmacokinetic Modeling and Simulation Guiding Clinical Trial Decisions

INTRODUCTION: There is an urgent need to develop new drugs to treat malaria due to increasing resistance to first-line therapeutics targeting the causative organism, Plasmodium falciparum (P. falciparum). One drug candidate is DM1157, a small molecule that inhibits the formation of hemozoin, which p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balevic, Stephen J., Raja, Shruti M., Randell, Rachel, Deye, Gregory A., Conrad, Thomas, Nakamura, Aya, Peyton, David H., Shotwell, Sandra, Liebman, Katherine, Cohen-Wolkowiez, Michael, Guptill, Jeffrey T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960550/ https://www.ncbi.nlm.nih.gov/pubmed/35184256 http://dx.doi.org/10.1007/s40121-022-00605-z

Ejemplares similares

Latter-stage preclinical developmental work on PL69/DM1157
por: Peyton, David
Publicado: (2014)

Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial
por: Balevic, Stephen J, et al.
Publicado: (2022)

Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial
por: Randell, Rachel L, et al.
Publicado: (2021)

Cefazolin Pharmacokinetics in Premature Infants
por: Balevic, Stephen J., et al.
Publicado: (2019)

Population Pharmacokinetics/Pharmacodynamics of 3,4‐Diaminopyridine Free Base in Patients With Lambert‐Eaton Myasthenia
por: Thakkar, Nilay, et al.
Publicado: (2017)

Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B
por: Guptill, J. T., et al.
Publicado: (2021)

1157. Clinical Safety, Efficacy, and Pharmacokinetics of Fosmanogepix, a Novel First-in-class Antifungal, in Patients with Renal Insufficiency: Subset Analysis from a Phase 2 Candidemia Trial
por: Bulpa, Pierre, et al.
Publicado: (2020)

Psychophysiology of positive and negative emotions, dataset of 1157 cases and 8 biosignals
por: Behnke, Maciej, et al.
Publicado: (2022)

1157. Determining the Clinical Utility of 16S rRNA in the Management of Pediatric Infections
por: Lim, Peter Paul, et al.
Publicado: (2021)

1157. GET IT OUT! Nurses and Clinical Quality Improvement Specialists Drive Initiative to Reduce Standardized Utilization Ratios for Indwelling Urinary Catheters in Hospitalized Patients
por: Martinez, Aldo, et al.
Publicado: (2019)

Reverse pharmacology for developing an anti-malarial phytomedicine. The example of Argemone mexicana
por: Simoes-Pires, Claudia, et al.
Publicado: (2014)

Towards optimal design of anti-malarial pharmacokinetic studies
por: Simpson, Julie A, et al.
Publicado: (2009)

1157. Optimal Isolation Periods Based on Time Interval to Elimination of Scabies After Topical Agent in the Real Clinical Practice
por: Park, Jebyung, et al.
Publicado: (2018)

P1157: PHASE II STUDY OF GLOFITAMAB, POSELTINIB AND LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE B CELL LYMPHOMAS
por: Min Byun, Ja, et al.
Publicado: (2023)

233. Safety of Ceftazidime-Avibactam (CZA) in Combination with Aztreonam (ATM) in a Phase I, Open-Label Study in Healthy Adult Subjects (COMBINE)
por: Lodise, Thomas, et al.
Publicado: (2022)

Comptel three-year search for galactic sources of $^{44}Ti$ gamma-ray line emission at 1.157 MeV
por: Dupraz, C, et al.
Publicado: (1997)

Clinical Manifestation of Patients With Atypical Hemolytic Uremic Syndrome With the C3 p.I1157T Variation in the Kinki Region of Japan
por: Matsumoto, Takeshi, et al.
Publicado: (2018)

Renal Damage in Recurrent Atypical Hemolytic Uremic Syndrome Associated with C3 p.Ile1157Thr Gene Mutation
por: Okabe, Masahiro, et al.
Publicado: (2020)

P1157: REAL-WORLD TREATMENT PATTERNS AND COMPARATIVE EFFECTIVENESS OF BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH MANTLE CELL LYMPHOMA
por: Shah, B., et al.
Publicado: (2022)

A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers
por: Chilengi, Roma, et al.
Publicado: (2011)

Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes
por: Balevic, Stephen J, et al.
Publicado: (2022)

An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants
por: Thakkar, Nilay, et al.
Publicado: (2016)

Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions
por: Souza Botelho, Mayra, et al.
Publicado: (2021)

SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys
por: Humbert, Michael, et al.
Publicado: (2008)

1157. The Clinical Impact of Casirivimab–Imdevimab Monoclonal Antibody Therapy (CIMAT) in COVID-19 patients: A real-world insight from India.
por: Kochuparambil, Jose J, et al.
Publicado: (2022)

The SMARCA4(R1157W) mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancer
por: Zeng, Xiangwei, et al.
Publicado: (2023)

Population Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone in Neonates Undergoing Cardiopulmonary Bypass
por: Hornik, Christoph P., et al.
Publicado: (2019)

Is "Malarial Cachexia" Purely Malarial?
por: Rogers, Leonard
Publicado: (1902)

Malarial Fevers and Malarial Parasites
Publicado: (1903)

Atypical Hemolytic Uremic Syndrome With the p.Ile1157Thr C3 Mutation Successfully Treated With Plasma Exchange and Eculizumab: A Case Report
por: Saito, Daiki, et al.
Publicado: (2019)

Estimation of Body Fat Percentage for Clinical Pharmacokinetic Studies in Children
por: Green, Thomas P., et al.
Publicado: (2020)

SAS Graphics for Clinical Trials by Example
por: Harris, Kriss, et al.
Publicado: (2020)

Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid
por: Salerno, Sara N., et al.
Publicado: (2017)

The Natural Production of Malaria and the Means of Making Malarial Countries Healthier
por: Crudeli, Conrad Tommasi
Publicado: (1885)

Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development
por: Zaloumis, Sophie, et al.
Publicado: (2012)

Functional, biochemical, molecular and clinical characterization of antithrombin c.1157T>C (p.Ile386Thr), a recurrent Polish variant with a founder effect
por: Weronska, Anna, et al.
Publicado: (2023)

Physiologically Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support: Fluconazole in Children on ECMO
por: Watt, Kevin M., et al.
Publicado: (2018)

Need for optimized dosages in the design of comparative clinical trials of anti-malarial drugs
por: Krishna, Sanjeev, et al.
Publicado: (2022)

Characterizing Pharmacokinetics in Children With Obesity—Physiological, Drug, Patient, and Methodological Considerations
por: Gerhart, Jacqueline G., et al.
Publicado: (2022)

Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds
por: Marcsisin, Sean R, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fogolg8q6g9muuocbcpm6ho9go